Martin Landry

Cannabis stocks were mostly higher Monday after Canopy Growth Corp (NYSE: CGC) received positive coverage from an analyst. The Analysts GMP Securities' Martin Landry upgraded Canopy Growth from Hold to Buy with a price target lifted from $65 to $72. The Thesis Canopy Growth last week secured...

Canadian cannabis company Canopy Growth Corp (NYSE: CGC) reported third-quarter results last week that were highlighted by the first revenue beat in the past four quarters, but a gross margins of 22 percent was the worst seen in three years, according to GMP. The Analyst GMP Securities' Martin...

Cannabis stock Cronos Group, Inc. (NYSE: CRON) has been one of the hottest stocks in the market in 2019, gaining 115 percent year-to-date. However, one analyst said Tuesday Cronos stock has come too far too fast. The Analyst GMP analyst Martin Landry downgraded Cronos from Buy to Hold and...

Canadian cannabis company Canopy Growth Corp (NYSE: CGC) confirmed Monday that it received a license to produce and process hemp in New York, prompting GMP to turn incrementally bullish on the stock. The Analyst Analyst Martin Landry maintains a Buy rating on Toronto-listed Canopy Growth ...

Cronos Group Inc (NASDAQ: CRON) stock bounced back by 8.8 percent Friday after a 30-percent Thursday sell-off. The decline stemmed from accusations from Citron Research that Cronos is deceiving investors by not disclosing the size of its distribution agreements with Canadian provinces. Citron...